Intercept Pharmaceuticals Investor Relations Material

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, is developing obeticholic acid (OCA), an agonist of the farnesoid X receptor, which is in Phase III clinical trials for the treatment of primary biliary cirrhosis; OCA that is in Phase IIb clinical trials for treating nonalcoholic steatohepatitis; and OCA that is Phase II clinical trial to treat fibrosing cholestatic hepatitis. The company was incorporated in 2002 and is headquartered in New York, New York.